CAMBRIDGE, Mass., Nov. 29, 2017 — Codiak BioSciences, Inc., the leading exosome therapeutics company, today announced the closing of a Series C financing round of $76.5 million. In its two years as a company Codiak’s funding totals $168.5 million. Codiak’s initial investors, including ARCH Venture Partners, Flagship Pioneering, Fidelity Management and Research Company, the Alaska Permanent Fund, and Alexandria Venture Investments, participated in the Series C round, and were joined by new investors, including Qatar Investment Authority, Boxer Capital of the Tavistock Group, Sirona Capital, EcoR1 Capital, and Casdin Capital.
Avalon GloboCare Acquires Leading Beijing Exosome Technology Company
Avalon Forms Subsidiary U.S. Company, GenExosome Technologies Inc., for the Global Advancement of Exosome Technology for Diagnosis and Treatment of Diseases
FREEHOLD, NJ–(October 30, 2017) – Avalon GloboCare Corp. (OTCQB: AVCO), a leading global developer of cell-based technologies, announced today that its majority-owned subsidiary GenExosome Technologies Inc. (GenExosome) acquired 100% of the outstanding capital stock of Beijing Jieteng (Beijing GenExosome) Biotech Co. Ltd. Concurrently, GenExosome entered into and closed an Asset Purchase Agreement with Dr. Yu Zhou, CEO of GenExosome Beijing, pursuant to which GenExosome acquired all assets, including all intellectual property, patents and patent applications held by Dr. Zhou pertaining to the business of researching, developing and commercializing exosome technologies. Additional details of the transaction are available in the Company’s form 8-K filed with the Securities & Exchange Commission on October 27, 2017, and is available at www.sec.gov.
WideCells’ CellPlan Insurance is Live – 1st Sales Made to Biovault’s Base of Cord Blood Banks
World first stem cell insurance plan, CellPlan, secures maiden sales agreement signaling commencement of commercial roll out.
CellPlan Limited (‘CellPlan’), which has developed the world’s first stem cell healthcare insurance plan and medical concierge service, has cemented its agreement with Biovault Technical Ltd (‘Biovault’), the UK’s largest private human tissue storage facility via a definitive agreement. CellPlan is part of London-listedWideCells Group plc, the healthcare services company focused on providing end-to-end stem cell services. [Read more…]
Global Cooperation – MD Anderson and NIH to Fund Clinical Trial Combining Mesoblast Technologies
MD Anderson Cancer Center and National Institutes of Health to Fund Trial Combining 2 Proprietary Mesoblast Technologies for Rapid Engraftment of Stem Cell Transplants in Cancer Patients
New York, USA; and Melbourne, Australia; December 6, 2016: Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced that MD Anderson Cancer Center (MDACC) in Texas and the United States National Institutes of Health (NIH) will fund a clinical trial combining Mesoblast’s two synergistic proprietary technologies, Mesenchymal Precursor Cell (MPC)-based expansion and ex-vivo fucosylation of hematopoietic stem cells (HSCs) for cord blood transplantation in cancer patients. The trial will provide clinical data on whether the combination of these two technologies synergistically facilitates more rapid cord blood HSC engraftment for bone marrow transplant patients than can be achieved by either technology alone.
The number of allogeneic bone marrow transplants performed globally each year could be substantially increased beyond the current 30,000, for cancer and non-cancer indications, if safe and effective alternative sources of allogeneic HSCs are available, such as cord blood, for patients who cannot find a matched donor. Unfortunately, cord blood transplants are associated with prolonged engraftment times due to insufficient numbers and inadequate homing capacity of cord blood HSCs, adversely impacting their clinical outcomes. [Read more…]
This Week in Stem Cells – MSCs, Exosomes, Sertoli Cells, and More
It was a interesting week in the stem cell sector, with new releases about MSCs, exosomes, Sertoli cells, and more. Check out this coverage of the stem cell industry and let me know what you think?
Breaking News! Altucell Releases Evidence in Support of Microencapsulated Sertoli Cells for Reversal of Diabetes
According to the Center for Disease Control (CDC), 29.1 million people or 9.3% of the U.S. population has diabetes, including an estimated 8.1 million who are undiagnosed. One small but powerful company working in this area is AltuCell, a company whose mission is to find a cure to diabetes. In a recent peer-review article published in the journal Xenotransplantation (September 2016), AltuCell’s medical lead Dr. Giovanni Luca reported a preclinical breakthrough utilizing microencapsulated Sertoli cells to establish reversal of diabetes in a mouse model. An important voice in support of the recent findings was Dr. David White of the Schulich School of Medicine who released an article about the breakthrough titled, “A Cure for Type 2 Diabetes?”
What are Exosomes? The Exosome Revolution is Here
What are exosomes? This is an important question, because exosomes have recently exploded in popularity. Although exosomes were discovered more than 30 years ago, it was not until recently that the scientific community began to give credit to exosomes for a range of promising traits. Ten years ago in 2006, there were only 76 articles published about exosomes. Today, there are more than 4,400 articles published about exosomes, of which 1,088 (~25%) were released in the 2016 calendar year. Clearly, there has been an explosion of interest in exosomes, making it important for the scientific community to understand the functionality and importance of these nano-sized vesicles. [Read more…]